@article{ATM33166,
author = {Wan Li and Xiangjin Zheng and Liwen Ren and Weiqi Fu and Jinyi Liu and Jun Xv and Shiwei Liu and Jinhua Wang and Guanhua Du},
title = {Epigenetic hypomethylation and upregulation of GD3s in triple negative breast cancer},
journal = {Annals of Translational Medicine},
volume = {7},
number = {23},
year = {2019},
keywords = {},
abstract = {Background: Breast cancer remains a major health problem in the world. Triple-negative breast cancer (TNBC) is an aggressive subtype with very poor prognosis. Up to now, the mechanism behind TNBC’s activity is still unclear and no candidate drug target has been identified. Thus, it is of critical importance to elucidate the pathways in TNBC and identify the relevant biomarkers. Recent studies showed that ganglioside D3 synthase (GD3s) played a very important role in development of cancers. However, the physiological functions and associated pathways of GD3s in TNBC are still unclear.
Methods: In silico analysis of the expression of GD3s in TNBC was conducted using The Cancer Genome Atlas (TCGA) and Oncomine databases. The proliferation of breast cancer cells was measured by MTT assay, colony formation by the soft agar method, and migration and invasion using Boyden chamber inserts. The methylation level of the gene encoding GD3s, ST8SIA1, in specimens was assessed by qMS-PCR and in silico using the UCSC gene browser. Protein expression was examined via immunohistochemistry (IHC), qRT-PCR and Western immunoblotting.
Results: In silico analysis showed a higher GD3s expression in ER− than ER+ breast cancers and GD3s was also highly expressed in TNBC compared to other types of breast cancers. The elevated GD3s expression in TNBC cells and tissues was associated with hypomethylation of the ST8SIA1 gene. Overexpression of GD3s in human breast cancer cells increased their proliferation, migration, invasion and colony formation ability. GD3s expression in breast cancers was closely associated with relapse-free survival (RFS) and overall survival (OS).
Conclusions: In summary, these results suggest that GD3s may be a potential biomarker and drug target in treatment of TNBC.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/33166}
}